Ignite Creation Date:
2024-05-05 @ 10:21 PM
Last Modification Date:
2024-10-26 @ 10:17 AM
Study NCT ID:
NCT01088906
Status:
TERMINATED
Last Update Posted:
2015-07-07
First Post:
2010-03-15
Brief Title:
Study of Pemetrexed Plus Cisplatin as First-line Therapy in Patients With Advanced Non-squamous NSCLC
Sponsor:
Spanish Lung Cancer Group
Organization:
Spanish Lung Cancer Group
Study Overview
Official Title:
Study of Pemetrexed Disodium Plus Cisplatin as First-line Therapy in Patients With Advanced Non-squamous Cell Lung Cancer a Phase IIA Pharmacogenomic Trial
Status:
TERMINATED
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
No safety reasons Low recruitment
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
Phalcis
Brief Summary:
This is a study of pemetrexed disodium plus cisplatin as first-line therapy in patients with advanced non-squamous cell lung cancer This is a phase IIA pharmacogenomic trial
Detailed Description:
This is a non-randomized phase IIA pharmacogenomic open label uncontrolled efficacy study in patients with advanced non-squamous cell lung cancer as a first line therapy
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2009-011327-31 | EUDRACT_NUMBER | None | None |